The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: a new treatment approach.
Weintraub
Jennifer
J
Division of Plastic & Reconstructive Surgery, Stanford University, 770 Welch Road, 4th floor, Stanford, CA 94305, USA. jenniferweintraub1@juno.com
Satterwhite
Thomas
T
Allo
Maria
M
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001753:Blast Injuries / Q000382:microbiology*; D002056:Burns / Q000382:microbiology*; D016638:Critical Illness; D006801:Humans; D008297:Male; D008875:Middle Aged; D011486:Protein C / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated